 |
 |
 |
 |
 |
 |
 |
||
|
Juvaris Management and Advisory Team:
Prior to Dendreon, he held senior management roles in marketing and business development with Algos Pharmaceutical Corporation culminating in its sale to Endo Pharmaceuticals for $211M. Mr. Pickering was also employed by Johnson & Johnson's Ortho Pharmaceutical Corporation and Glaxo, Inc., where he was highly successful in positions of increasing responsibility in the area of sales and marketing. Mr. Pickering earned his B.S. degree in marketing from the Pennsylvania State University in University Park, PA and his MBA degree with honors from Georgetown University in Washington, DC.
Prior to becoming co-Founder and CEO of Juvaris Biotherapeutics Mr. Cleary was President, CEO and a Director at Genteric, Inc. advancing its protein drug delivery technology platforms. Between 1999 and 2002 under his direction, the company raised $32 million in two venture investments and he developed Genteric into a leader in non-viral gene delivery. Mr. Cleary was co founder, President and CEO of CardioGene Therapeutics, a leading cardiovascular gene therapy company, from its inception in 1996 until its successful merger with Boston Scientific Corporation in 1998. From 1993 to 1994, he was President, CEO and a Director of Theragen, a diversified gene therapy company, which he successfully merged, with GenVec, Inc. of Rockville, Maryland. From 1994 to 1996, he served as a member of the Board of Directors of GenVec, Inc. From 1986 to 1993, he was Group Vice President and Chief Financial Officer of Cytogen Corporation, a biotech company engaged in the development of cancer diagnostics and therapies using monoclonal antibodies. Prior to joining Cytogen, Mr. Cleary held several senior management positions with Johnson & Johnson over a 14-year career. While serving as Vice President of Operations at J&J's medical device subsidiary Iolab Corporation between 1980 and 1986 the company enjoyed compound growth rates of 40% in sales and 50% in income on revenues in excess of $100 million.
Dr. Warner most recently completed a three-year association with
Collateral Therapeutics, Inc. as Vice President of Research and
Technology advancing their cardiovascular gene therapy and cardiomics
programs. Prior to Collateral Therapeutics, Dr. Warner held VP-level
positions at Valentis, Inc. and Inex Pharmaceuticals Corporation.
Dr. Warner was previously affiliated with Chiron-Viagene (formerly
Viagene, Inc.) for eight years (1988-1995) where he served in various
supervisory positions including Director, Immunobiology as well
as Head of the HIV immunotherapeutic program. This work resulted
in the initiation of one of the first gene therapy genetic immunization
phase II clinical trials for HIV patients. Dr. Warner was also a
Senior Scientist at the Johnson & Johnson Biotechnology Center
from 1985 to 1988, developing synthetic peptide vaccines. Dr. Warner's
scientific training includes five years as a postdoctoral fellow
at The Salk Institute for Biological Studies and the University
of California, San Diego involved in the study of innate immune
effector systems (cytokines and natural killer cells) and adaptive
immune responses (cellular and humoral). Dr. Warner earned his Ph.D.
in microbiology/immunology from the State University of New York,
Buffalo.
Ms. Gonzaga brings over 13 years of financial management experience, four years of which was spent in public accounting and the last nine in the medical device industry in both established and early stage companies. Most recently she was with Thoratec Corporation where she held several financial management positions before being named Sr. Strategic Finance Manager. Ms. Gonzaga was responsible for all aspects of consolidated budgeting and planning for multiple divisions, quarterly investor relations for all financial press releases including analyst’s reviews, and worked extensively with business development in all aspects of M&A and other material agreements. Prior to Thoratec Corporation, Ms. Gonzaga held progressive positions with Stryker Corporation, Smith & Nephew, Inc. and with Oratec Interventions, Inc. where she was a key contributor in the Initial Public Offering of the company, the acquisition of a small company and later the acquisition to Smith & Nephew.
Dr. Bussey with over 20 years experience, is recognized as a leader in clinical process development and manufacturing, He is a skilled team builder and has lead multiple national/international teams ensuring successful technology transfers and production runs at Contract Manufacturing Organizations (CMOs). His responsibility includes Fermentation, Purification, QC/Analytical, Formulation, Fill/Finish, Facilities and IT. Previously Dr. Bussey served as Vice President of Bioprocessing for Valentis Inc. While at Valentis Inc.(12+ yrs), his team developed patented technologies for both plasmid DNA purification and formulation, both being critical for Juvaris’ programs. Prior Valentis Inc., Dr. Bussey worked for Pel Freez Biologicals producing nucleic acid, viral and protein based products. He also served in academic positions at the University of Illinois and Georgia State University. Dr. Bussey earned his Ph.D. in Microbiology from the University of California at Davis.
In 1996, Dr. Fairman began his industrial experience with AmCell Corporation working to develop technologies to isolate fetal cells from maternal blood for cytogenetic analysis. During this time he was one of three inventors on a patent for PCR additives. In 1997 Dr. Fairman joined Valentis, Inc., where he managed the assay development group and conducted preclincial efficacy and toxicity studies. He is also a consultant on quantitative PCR/RT-PCR and in-situ PCR/RT-PCR at the University of California, Davis, Applied Biosystems and Celera Diagnostics. Most recently, Dr. Fairman was the Director of Pharmacogenomics
Research at Clingenix Inc. where he directed research in the application
of pharmacogenomics to clinical development. During his time at
Clingenix, Dr. Fairman was inventor on several patents involving
the application of pharmacogenomics technologies.
Ms. Sisti began her career in Research with Genetics Institute and Cypress Bioscience. It eventually led her into Clinical Development as a Clinical Research Associate, Clinical Project Manager, and Clinical Research Manager. Her solid reputation has evolved from extensive experience within contract research organizations, biotechnology, pharmaceutical and vaccine companies (Parexel, Genzyme, Pfizer, Acambis, GSK Biologics). She previously provided clinical operations consultancy for multiple vaccine companies.
Mr. Morse has an MBA from Santa Clara University and both MS and
BS degrees from Stanford University, where he was a member of Phi
Beta Kappa Honor Society.
His current major research interests are in immunotherapeutic approaches to the treatment of cancer and chronic infectious diseases. Prior to developing a cancer gene therapy program, his past research has studied animal models of chronic viral infection (feline immunodeficiency virus and feline leukemia virus), as well as the role of CD8+ T cells in immunity to tuberculosis. Dr. Dow is experienced in the discovery and application of gene
therapy to oncologic and immune-mediated diseases and holds patents
related to cell regulation with gene therapy. He also has several
pending patents, including those that constitute the enabling technology
for Juvaris BioTherapeutics, Inc.
|
